Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
8 results
  • Cervical Cancer, Liver Cancer, Gastric (Stomach) Cancer

20-577          Phase I

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Sarcoma, Gallbladder and Bile Duct Cancers, Metastatic/Advanced Cancer, Liver Cancer, Brain Tumors

20-487          Phase I

A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (View details on clinicaltrial.gov)

  • Metastatic/Advanced Cancer, Esophageal Cancer, Lung Cancer, Brain Tumors, Metastatic, Gastric (Stomach) Cancer, Liver Cancer

19-812          Phase I

A Phase 1, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations in MET (View details on clinicaltrial.gov)

  • Pancreatic Cancer, Sarcoma, Liver Cancer, Bladder Cancer, Gastric (Stomach) Cancer, Endometrial Cancer, Esophageal Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on clinicaltrial.gov)

  • Liver Cancer

20-570          Phase I

A pilot study of neoadjuvant stereotactic beam radiation therapy followed by atezolizumab and bevacizumab in resectable hepatocellular carcinoma (View details on clinicaltrial.gov)

  • Liver Cancer

21-410          N/A

A prospective, multicenter, open-label single arm study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres on duration of response (DoR) and objective response rate (ORR) in unresectable hepatocellular carcinoma (HCC) patients (DOORwaY90 Study) (View details on clinicaltrial.gov)

Showing 1 - 10 of 8 results